Fmr LLC reduced its holdings in Steris PLC (NYSE:STE) by 17.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,601,608 shares of the medical equipment provider’s stock after selling 563,195 shares during the period. Fmr LLC owned approximately 3.08% of Steris worth $273,195,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. ARP Americas LP acquired a new stake in shares of Steris during the 2nd quarter worth approximately $212,000. Empirical Finance LLC acquired a new stake in shares of Steris during the 2nd quarter worth approximately $216,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Steris during the 2nd quarter worth approximately $218,000. Intrust Bank NA acquired a new stake in shares of Steris during the 2nd quarter worth approximately $234,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Steris by 739.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,343 shares of the medical equipment provider’s stock worth $246,000 after purchasing an additional 2,064 shares in the last quarter. 88.76% of the stock is currently owned by institutional investors.
Shares of STE stock opened at $107.83 on Wednesday. The company has a current ratio of 2.65, a quick ratio of 2.02 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $8.95 billion, a P/E ratio of 25.98 and a beta of 1.06. Steris PLC has a one year low of $82.88 and a one year high of $117.48.
Several analysts have recently weighed in on the company. KeyCorp lifted their price objective on Steris from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 9th. Stephens reissued a “buy” rating and set a $125.00 price objective on shares of Steris in a report on Thursday, August 9th. JMP Securities lifted their price objective on Steris from $113.00 to $125.00 and gave the stock a “market outperform” rating in a report on Thursday, August 9th. Finally, Zacks Investment Research raised Steris from a “sell” rating to a “hold” rating in a report on Thursday, September 20th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Steris currently has an average rating of “Buy” and an average target price of $100.86.
In related news, VP Karen L. Burton sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $114.39, for a total value of $148,707.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 2.38% of the stock is owned by insiders.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
See Also: Are analyst ratings accurate?
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris PLC (NYSE:STE).
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.